EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers

Roberto Chiarle iD, Chiara Ambrogio iD

Molecular Oncology · 2023-11 · 17 (11) · 2215-2217

DOI: 10.1002/1878-0261.13547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 31.10.2023. Verfasst von Roberto Chiarle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Oncogenes, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Associazione Italiana per la Ricerca sul Cancro, Giovanni Armenise-Harvard Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical paradigms. These represent an opportunity and a challenge for researchers and clinicians to delve deeper into the intricate dynamics of cancer development and response to treatment. By directly inhibiting key driver oncogenes involved in tumor initiation and progression, scientists have an unprecedented opportunity to conduct longitudinal and clonal evolutionary studies of how cancer cells adapt, rewire, and exploit conflictive or overlapping signaling dependencies in response to treatment in vitro and in vivo . This challenge has to be progressively resolved to discover more effective and personalized cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OncogenesNeoplasmsHumansCell Transformation, NeoplasticSignal TransductionMutation

Stichwörter der Autor:innen

driver oncogenesdrug resistancesignaling rewiring

Autor:innen und Institutionen

  • Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

ORCID-Profile: Roberto Chiarle, Chiara Ambrogio

Förderung

  • NCI NIH HHS
  • Associazione Italiana per la Ricerca sul Cancro
  • Giovanni Armenise-Harvard Foundation
  • H2020 European Research Council
  • Leukemia and Lymphoma Society

Zitieren

APA

Chiarle, R., & Ambrogio, C. (2023). Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers. Molecular Oncology, 17(11), 2215-2217. https://doi.org/10.1002/1878-0261.13547

Vancouver

Chiarle R, Ambrogio C. Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers. Molecular Oncology. 2023;17(11):2215-2217. doi:10.1002/1878-0261.13547

BibTeX
@article{Chiarle2023,
  author = {Chiarle, Roberto and Ambrogio, Chiara},
  title = {Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers},
  journal = {Molecular Oncology},
  year = {2023},
  volume = {17},
  number = {11},
  pages = {2215--2217},
  doi = {10.1002/1878-0261.13547}
}
Kostenlos starten →